Intrathecal baclofen (ITB) was approved for the
treatment of spasticity of cerebral origin in 1996.
ITB is a surgically implanted system used to
control spasticity by infusing baclofen directly into
the spinal canal and around the spinal cord[24].
Baclofen inhibits spasticity by blocking excitatory
neurotransmitters in the spinal dorsal horn. ITB
maximizes the dose delivered to spinal receptors
and minimizes the side effects associated with oral
baclofen[25].